Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1962 1
1965 2
1966 1
1967 1
1969 1
1970 1
1971 4
1973 2
1974 1
1975 1
1976 1
1977 1
1980 6
1981 8
1982 2
1983 10
1984 10
1985 5
1986 6
1988 5
1989 6
1990 8
1991 12
1992 8
1993 14
1994 15
1995 10
1996 10
1997 8
1998 11
1999 14
2000 16
2001 15
2002 20
2003 17
2004 11
2005 20
2006 10
2007 26
2008 26
2009 21
2010 38
2011 35
2012 32
2013 28
2014 32
2015 29
2016 39
2017 32
2018 32
2019 48
2020 51
2021 25
Text availability
Article attribute
Article type
Publication date

Search Results

733 results
Results by year
Filters applied: . Clear all
Page 1
Chronic inflammation and cytokines in the tumor microenvironment.
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Landskron G, et al. Among authors: de la fuente m. J Immunol Res. 2014;2014:149185. doi: 10.1155/2014/149185. Epub 2014 May 13. J Immunol Res. 2014. PMID: 24901008 Free PMC article. Review.
The role of bevacizumab in the treatment of glioblastoma.
Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. Diaz RJ, et al. Among authors: de la fuente mi. J Neurooncol. 2017 Jul;133(3):455-467. doi: 10.1007/s11060-017-2477-x. Epub 2017 May 19. J Neurooncol. 2017. PMID: 28527008 Review.
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Mellinghoff IK, et al. Among authors: de la fuente mi. J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530764 Clinical Trial.
Exosome-mimetic nanoplatforms for targeted cancer drug delivery.
Vázquez-Ríos AJ, Molina-Crespo Á, Bouzo BL, López-López R, Moreno-Bueno G, de la Fuente M. Vázquez-Ríos AJ, et al. Among authors: de la fuente m. J Nanobiotechnology. 2019 Jul 18;17(1):85. doi: 10.1186/s12951-019-0517-8. J Nanobiotechnology. 2019. PMID: 31319859 Free PMC article.
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sørensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzàlez-Farré X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM. Smyth LM, et al. Among authors: de la fuente mi. Cancer Discov. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. Epub 2019 Dec 5. Cancer Discov. 2020. PMID: 31806627 Free PMC article. Clinical Trial.
Where Could Research on Immunosenescence Lead?
De la Fuente M. De la Fuente M. Int J Mol Sci. 2019 Nov 25;20(23):5906. doi: 10.3390/ijms20235906. Int J Mol Sci. 2019. PMID: 31775238 Free PMC article.
Impact of Metabolism on Immune Responses.
Elkhal A, Rodriguez Cetina Biefer H, de la Fuente MA. Elkhal A, et al. Among authors: de la fuente ma. J Immunol Res. 2018 Jul 26;2018:5069316. doi: 10.1155/2018/5069316. eCollection 2018. J Immunol Res. 2018. PMID: 30148174 Free PMC article. No abstract available.
733 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page